Sezer A, Kilickap S, Gümüş M, et al. - In a multicenter, open-label, global, phase 3 study (EMPOWER-Lung 1), researchers tested cemiplimab (a programmed cell death 1 inhibitor) as first-line therapy for advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%. There were 710 eligible patients randomized (1:1) to cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. After disease progression, crossover from chemotherapy to cemiplimab was permitted. According to findings, significantly improved overall survival and progression-free survival were conferred by cemiplimab monotherapy vs chemotherapy in patients having advanced non-small-cell lung cancer with PD-L1 of at least 50%. With cemiplimab, median progression-free survival was 8.2 months vs 5.7 months with chemotherapy. In the intention-to-treat population, significant improvements in overall survival and progression-free survival were also observed with cemiplimab, despite a high crossover rate (74%). Cemiplimab monotherapy offers a potential new therapeutic choice for this patient group.